natgillin/translations-raw huggingface dataset:
With regard to the in vitro susceptibility data, although there is no standardised methodology for determination of the MIC for antibiotics against B. hyodysenteriae, it was evident that the majority of isolates fall outside the apparent wild-type population.
Podatki o občutljivosti in vitro kažejo, da čeprav ni standardizirane metodologije za določanje vrednosti MIK antibiotikov proti B. hyodysenteriae, večina izolatov ne sodi v populacijo sevov divjega tipa.
Despite the lack of standardised procedures for MIC testing of antimicrobial agents against mycoplasmas and clinical breakpoints, based on the MIC data provided it could be concluded that the susceptibility pattern of M. hyopneumoniae to lincomycin has not changed significantly over the last 20-25 years.
Kljub pomanjkanju standardiziranih postopkov za določanje MIK protimikrobnih zdravil proti mikoplazmam in kliničnih mejnih vrednosti, ki temeljijo na podatkih MIK, je mogoče sklepati, da se vzorec občutljivosti M. hyopneumoniae za linkomicin v zadnjih 20-25 letih ni bistveno spremenil.
Nevertheless, based on the MIC data provided including the study conducted by the marketing authorisation holder in 2016, it could be concluded that the susceptibility pattern of M. hyopneumoniae to lincomycin has not changed significantly over the last 20-25 years.
Kljub temu je bilo možno na podlagi predloženih podatkov o vrednostih MIK in študije, ki jo je imetnik dovoljenja za promet opravil leta 2016, zaključiti, da se vzorec občutljivosti M. hyopneumoniae za linkomicin v zadnjih 20-25 letih ni bistveno spremenil.
Do not use in cases of known hypersensitivity to the active substance or to any of the excipients.
Ne uporabite v primerih preobčutljivosti na učinkovino, na dodatek ali na katero koli pomožno snov.
preferable; based on the data available and taking into account the variability of water intake and hence the dose ingested by the treated animals, a dose rate of 5 mg lincomycin per kg of body weight for 7 days was proposed.
Prednost ima ena (optimalna) velikost odmerka; na podlagi razpoložljivih podatkov in ob upoštevanju spremenljivosti vnosa vode in posledično odmerka, ki ga zaužijejo zdravljene živali, je bil predlagan odmerek 5 mg linkomicina na kg telesne mase 7 dni zapored.
Dosage (mg product per kg body weight per day)
Odmerek (mg zdravila na kg telesne mase na dan)
In addition, there is a lack of clinical breakpoints for both M. hyopneumoniae and C. perfringens.
Poleg tega ni kliničnih mejnih vrednosti za M. hyopneumoniae in C. perfringens.
Where possible, therapy should be based on local (regional, farm level) epidemiological information concerning the response of enzootic pneumonia/necrotic enteritis to treatment with lincomycin.”
Če je mogoče, mora zdravljenje temeljiti na lokalnih (regionalnih, na ravni kmetije) epidemioloških informacijah glede odziva enzootske pljučnice/nekrotičnega enteritisa na zdravljenje s linkomicinom.“
White high density polyethylene (HDPE) bottle containing 150 g or 1.5 kg powder for use in drinking water with a tamper evident low density polyethylene (LDPE) lid.
Bela plastenka iz polietilena visoke gostote (HDPE), ki vsebuje 150 g ali 1,5 kg praška za uporabo v pitni vodi s pokrovčkom iz polietilena nizke gostote (LDPE).
Repeated dosing of pigs with daily oral doses of 22 mg lincomycin/kg body weight for 3 days indicated no accumulation of lincomycin in the species, with no detectable serum levels of antibiotic after 24 hours post administration.
Ponavljajoče se odmerjanje prašičem, z dnevnimi peroralnimi odmerki 22 mg linkomicina / kg telesne mase za 3 dni ni nakazovalo kopičenja lincomicina pri tej živalski vrsti, pri čemer se po 24 urah po dajanju ne zaznavajo serumske vrednosti antibiotika.
For chickens, the currently authorised dose and the harmonised proposal was to administer 3-6 mg lincomycin per kg of body weight daily for 7 consecutive days.
Za piščance je trenutno odobreni odmerek in usklajeni predlog odmerka 3-6 mg linkomicina na kg telesne mase na dan 7 dni zapored.
Lincomycin is a lincosamide antibiotic derived from Streptomyces lincolnensis which inhibits protein synthesis.
Linkomicin je antibiotik iz skupine linkozamidov in je proizvod bakterije Streptomyces lincolensis, ki inhibira sintezo beljakovin.
Use of the veterinary medicinal product deviating from the instructions given in the summary of product characteristics may increase the prevalence of bacteria resistant to the lincomycin and may decrease the effectiveness of treatment with other lincosamides, macrolides and streptogramin B due to the potential for cross-resistance.
Uporaba zdravila za uporabo v veterinarski medicini, ki odstopa od navodil, navedenih v povzetku glavnih značilnosti zdravila, lahko poveča razširjenost bakterij, odpornih na linkomicin, in lahko zmanjša učinkovitost zdravljenja z drugimi linkozamidi, makrolidi in streptogramini B zaradi možnosti navzkrižne odpornosti.
A dosage greater than 10 mg lincomycin per kg of body weight may cause diarrhoea and loose stools in pigs.
Večji odmerki od 10 mg linkomicina/kg telesne mase lahko povzročijo drisko in mehko blato pri prašičih.
A single oral administration of lincomycin hydrochloride, at dose levels of approximately 22, 55 and 100 mg/kg body weight in pigs, resulted in dose related lincomycin serum levels, detected for 24-36 hours after administration.
Enkratna peroralna administracija linkomicinijevega klorida pri odmerkih približno 22, 55 in 100 mg / kg telesne mase pri prašičih omogoča vsebnost serumskega odmerka linkomicina, ugotovljeno 24 do 36 ur po dajanju.
Pigs, poultry (broilers)
Prašiči Perutnina (brojlerji)
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT IN NAČIN UPORABE
• Indications
• indikacije,
Lincomycin is active against some gram-positive bacteria (Clostridium perfringens) and mycoplasmas (Mycoplasma hyopneumoniae).
Lincomycin deluje proti nekaterim gram- pozitivnim bakterijam (Clostridium perfringens) in mikoplazmam (Mycoplasma hyopneumoniae).
Regarding the determination of the withdrawal period, no residue depletion studies have been conducted with Lincocin in chickens using a modern (HPLC) assay method.
Kar zadeva določitev karence, študije o izločanju ostankov linkomicina niso bile opravljene s sodobno analizno metodo (HPLC).
Pharmacotherapeutic group: Antibacterials for systemic use; Lincosamides.
Farmakoterapevtska skupina: Protimikrobne učinkovine za sistemsko zdravljenje, Linkozamidi
Meat and offal: 5 days.
Meso in organi : 5 dni.
• the scope of the referral was the harmonisation of the summary of product characteristics, labelling and package leaflet;
• namen napotitve je bila uskladitev povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo;
The safety of the veterinary medicinal product has not been established during pregnancy, lactation or lay in the target species.
Varnost zdravila v obdobju brejosti, laktacije ali nesnosti ni bila ugotovljena.
Based on the observed depletion pattern, a 5-day withdrawal period was shown to be appropriate for the combination product.
Na podlagi ugotovljenega vzorca izločanja je bilo dokazano, da je za kombinirano zdravilo primerna petdnevna karenca.
The susceptibility of Mycoplasma hyopneumoniae to antimicrobial agents is difficult to test in vitro owing to technical constraints.
Občutljivost Mycoplasma hyopneumoniae na protimikrobno učinkovino je težko preskušati in vitro zaradi tehničnih omejitev.
Resistance to lincomycin is frequently conferred by plasmid-borne factors (erm genes) coding for methylases modifying the ribosomal binding site and frequently leading to cross-resistance to other antimicrobials of the macrolides, linconsamides and streptogramins group.
Odpornost na linkomicin pogosto povzročajo prenosljivi plazmidi (geni), ki kodirajo metilaze, ki spreminjajo mesto vezave ribosomov in pogosto vodijo do navzkrižne odpornosti proti drugim protimikrobnim zdravilom iz skupin makrolidov, linkozamidov in streptograminov.
The active substance lincomycin is a lincosamide antibiotic and is produced by Streptomyces lincolnensis.
Zdravilna učinkovina linkomicin je linkozamidni antibiotik, ki ga tvori Streptomyces lincolnensis.
CVMP opinion for a referral procedure (EMEA/V/A/110) under Article 35 of Directive 2001/82/EC for veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and/or poultry - link procedure, the CVMP concluded that this indication should also be deleted from the product information for Lincocin.
1 CVMP opinion for a referral procedure (EMEA/V/A/110) under Article 35 of Directive 2001/82/EC for veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and/or poultry - link
Do not administer, and do not allow access to water containing lincomycin, to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants as this could result in severe gastro-intestinal disturbance.
Zdravila ne dajemo in ne dovolimo dostopa do pitne vode, ki vsebuje linkomicin kuncem, hrčkom, morskim prašičkom, činčilam, konjem ali prežvekovalcem, saj to lahko vodi v resnejše gastrointestinalne motnje.
Bottle of 150 g Bottle of 1.5 kg
Plastenka s 150 g ali 1,5 kg
Regarding laying hens, there are no data to support a withdrawal period in eggs; hence, the use of the product should not be authorised in laying birds producing eggs for human consumption.
Kar zadeva kokoši nesnice, ni podatkov, ki bi podprli karenco za jajca; zato se pri nesnicah, ki ležejo jajca za prehrano ljudi, ne sme dovoliti uporabe zdravila.
Lincocin is a powder for oral solution containing 400 mg lincomycin per gram product.
Zdravilo Lincocin je prašek za peroralno raztopino, ki vsebuje 400 mg linkomicina na gram zdravila.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po EXP. Rok uporabnosti zdravila se nanaša na zadnji dan v navedenem mesecu.
= ___ mg product per litre drinking water
= ___ mg zdravila na liter pitne vode
Medicated drinking water uptake can be affected by the severity of the disease.
Resnost bolezni lahko vpliva na vnos pitne vode.
Crossing the intestinal barrier, lincomycin is widely distributed to all tissues, especially the lungs and joint cavities; the volume of distribution is about 1 litre.
Pri prehajanju preko črevesne pregrade se linkomicin široko porazdeli v vsa tkiva, zlasti pljuča in sklepne votline; volumen porazdelitve je približno 1 L. Razpolovni čas izločanja linkomicina je večji od 3 ur.
Therefore, the high in vitro resistance level in B. hyodysenteriae constitutes a major uncertainty as to the clinical effectiveness of Lincocin.
Posledično veliko negotovost o klinični učinkovitosti zdravila Lincocin predstavlja visoka stopnja odpornosti in vitro pri B. hyodysenteriae.
Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet
Znanstveni zaključki in podlaga za dopolnilo povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo
As there were no data to support a withdrawal period in laying hens, the use of the product should not be authorised in laying birds producing eggs for human consumption.
Ker ni bilo podatkov, ki bi podprli karenco pri kokoših nesnicah, se zdravilo ne sme odobriti za uporabo pri nesnicah, ki ležejo jajca za prehrano ljudi.
Special warnings for each target species:
Posebna opozorila za vsako ciljno živalsko vrsto
The CVMP acknowledged the difficulties in determining a single dose and agreed that although somewhat arbitrarily selected, the proposal for a dose rate of 5 mg lincomycin per kg of body weight for 7 days is acceptable.
Odbor CVMP je seznanjen s težavami pri določanju enega samega odmerka in se strinja, da je sprejemljiv predlog odmerka 5 mg linkomicina na kg telesne mase 7 dni zapored, čeprav je številka izbrana nekoliko arbitrarno.
The in vitro data from published literature and from the marketing authorisation holder's own study indicated that the MICs for lincomycin had wide ranges and were not unimodal.
Podatki in vitro iz objavljene literature in iz lastne študije imetnika dovoljenja za promet so pokazali, da so vrednosti MIK linkomicina imele širok razpon in niso bile porazdeljene unimodalno.
The in vitro data from published literature and from the marketing authorisation holder's own study indicated that the MIC distribution for lincomycin was wide and not unimodal.
Podatki in vitro iz objavljene literature in lastne študije imetnika dovoljenja za promet so pokazali, da je bila porazdelitev vrednosti MIK linkomicina široka in ni bila unimodalna.
PHARMACEUTICAL FORM Powder for use in drinking water.
FARMACEVTSKA OBLIKA Prašek za dajanje v vodo za pitje.
NAME OF THE VETERINARY MEDICINAL PRODUCT Lincocin 400 mg/g powder for use in drinking water
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Lincocin 400 mg/g prašek za dajanje v vodo za pitje
“The susceptibility of Mycoplasma hyopneumoniae to antimicrobial agents is difficult to test in vitro owing to technical constraints.
„Občutljivost bakterije Mycoplasma hyopneumoniae za protimikrobna zdravila je težko določiti in vitro zaradi tehničnih omejitev.
The provided clinical data demonstrated that Lincocin was effective in the treatment and metaphylaxis of necrotic enteritis caused by C. perfringens at a dose rate of 5 mg lincomycin per kg of body weight for 7 consecutive days.
Navedeni klinični podatki so pokazali, da je zdravilo Lincocin učinkovito pri zdravljenju in metafilaksi nekrotičnega enteritisa, ki ga povzroča C. perfringens, pri odmerku 5 mg linkomicina na kg telesne mase 7 dni zapored.
However, also see text under Special warnings for each target species.
Glejte tudi poglavje: Posebna opozorila za vsako ciljno živalsko vrsto
Concerning the indication for treatment and metaphylaxis of swine dysentery caused by Brachyspira hyodysenteriae and/or other bacteria susceptible to lincomycin, the marketing authorisation holder presented Minimum Inhibitory Concentration (MIC) data from several studies (including recent proprietary studies performed in 2016), clinical trials and studies from the scientific literature.
V zvezi z indikacijo za zdravljenje in metafilakso prašičje dizenterije, ki jo povzroča Brachyspira hyodysenteriae in/ali druge bakterije, občutljive za linkomicin, je imetnik dovoljenja za promet z zdravilom predložil podatke o minimalni inhibitorni koncentraciji (MIK) iz več študij (vključno z nedavnimi lastnimi študijami, opravljenimi leta 2016), kliničnih preskušanj in strokovne literature.
5.2 Pharmacokinetic particulars
5.1 Farmakodinamične lastnosti
The provided clinical data demonstrated that Lincocin was effective in the treatment and metaphylaxis of enzootic pneumonia caused by M. hyopneumoniae when administered at 10 mg lincomycin per kg of body weight for 21 consecutive days.
Predloženi klinični podatki so pokazali, da je zdravilo Lincocin učinkovito pri zdravljenju in metafilaksi enzootske pljučnice, ki jo povzroča M. hyopneumoniae, če se daje 10 mg linkomicina na kg telesne mase 21 dni zapored.
SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use.
INDIKACIJA(E) Pred uporabo preberite navodilo za uporabo.
In drinking water use
Uporabo v vodi za pitje
These conditions are usually selfcorrecting within 5-8 days without discontinuing the lincomycin treatment.
Znaki spontano izginejo po 5 do 8 dneh brez zdravljenja in ne da bi živalim prenehali dajati linkomicin.
Chickens: Meat and offal: 5 days.
Brojlerji : meso in organi: 5 dni.
On rare occasions, pigs given lincomycin-medicated water may develop diarrhoea/soft stools and/or mild swelling of the anus within the first 2 days after onset of treatment.
NEŽELENI UČINKI Pri prašičih se pri prevelikih odmerkih linkomicina lahko pojavi driska/mehko blato in/ali blag perianalni edem, 2 dni po začetku dajanja zdravila.
White to off-white powder.
Belo do umazano bel prašek.
Lincocin has also been proven to be efficacious in the treatment and metaphylaxis of necrotic enteritis caused by C. perfringens in chickens.
Zdravilo Lincocin je dokazano učinkovito pri zdravljenju in metafilaksi nekrotičnega enteritisa, ki ga povzroča C. perfringens pri piščancih.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali)
Lincocin has been shown to be efficacious for the treatment and metaphylaxis of enzootic pneumonia caused by M. hyopneumoniae in pigs.
Dokazano je bilo, da je zdravilo Lincocin učinkovito za zdravljenje in metafilakso enzootske pljučnice, ki jo povzroča M. hyopneumoniae pri prašičih.
Where possible, therapy should be based on local (regional, farm level) epidemiological information concerning the response of enzootic pneumonia/necrotic enteritis to treatment with lincomycin.
Kjer je to mogoče, naj zdravljenje temelji na lokalni (regionalni, na nivoju kmetije) epidemiološki situaciji, glede na odgovor na občutljivost ciljnih bakterij (pri enzootski pneumoniji in nekrotičnem enteristisu) na linkomicin.
With regard to the withdrawal period, a satisfactory residue depletion study in pigs was provided by the marketing authorisation holder.
Glede karence je imetnik dovoljenja za promet zagotovil zadovoljivo študijo izločanja ostankov pri prašičih.
Oral use (via drinking water)
Peroralna (uporabo v vodi za pitje)
The presence of the disease in the group must be established before the product is used.
Pred uporabo zdravila, mora biti bolezen potrjena.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
- redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
Loughlinstown
Loughlinstown Co. Dublin
As the conclusions from the aforementioned referral procedure (EMEA/V/A/110) can be extrapolated to the current
Ker se zaključki iz omenjenega napotitvenega postopka (EMEA/V/A/110) lahko ekstrapolirajo na trenutni postopek, je odbor CVMP zaključil, da je to indikacijo treba izbrisati tudi iz informacij o zdravilu za zdravilo Lincocin.
• Target species
• ciljne živalske vrste,
Withdrawal periods:
Odmerjanje:
Medicated drinking water should be freshly prepared every 24 hours.
Vsak dan pripravite svežo raztopino.
• the CVMP reviewed the summary of product characteristics, labelling and package leaflet proposed by the marketing authorisation holder and considered all the overall submitted data;
• odbor CVMP je pregledal povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo, ki jih je predlagal imetnik dovoljenj za promet z zdravilom, in proučil vse predložene podatke; odbor CVMP je priporočil spremembo dovoljenj za promet z zdravilom za zdravilo Lincocin in povezana imena, navedena v Prilogi I, za katera so v Prilogi III navedeni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo.
Enzootic pneumonia: 10 mg lincomycin per kg of body weight (corresponding to 25 mg product per kg bodyweight) for 21 consecutive days.
Enzootska pneumonija: odmerek 10 mg linkomicina na 1 kg telesne mase (kar ustreza 25 mg zdravila na 1 kg telesne mase) dajajte 21 zaporednih dni v vodi za pitje.
Pigs and chickens.
Prašiči in brojlerji.
Not authorised for use in laying birds producing eggs for human consumption.
Ni za uporabo pri pticah, ki proizvajajo ali so namenjene proizvodnji jajc za prehrano ljudi.
powder for use in drinking water
Peroralni prašek za uporabo v vodi za pitje
Not authorised for use in laying birds producing eggs for human consumption
Ni za uporabo pri pticah,ki proizvajajo ali so namenjene proizvodnji jajc za prehrano ljudi.
Necrotic enteritis: 5 mg lincomycin per kg of body weight (corresponding to 12.5 mg product per kg bodyweight) for 7 consecutive days.
Nekrotični enteritis: dnevni odmerek je 5 mg na kg telesne mase (kar ustreza 12,5 mg zdravila na 1 kg telesne mase).
Lincomycin
KARENCA
A single oral dose of 10 mg/kg body weight was administered to pigs to determine the bioavailability.
Za ugotavljanje biološke razpoložljivosti je bil prašičem dovolj en sam peroralni odmerek 10 mg / kg telesne mase.
Treatment and metaphylaxis of enzootic pneumonia caused by Mycoplasma hyopneumoniae.
Zdravljenje in metafilaksa enzootske pljučnice, ki jo povzroča Mycoplasma hyopneumoniae.
Treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens.
Zdravljenje in metafilaksa nekrotičnega enteritisa, ki ga povzroča Clostridium perfringens.
Pigs and chickens
Prašiči Perutnina
In support of the indication for treatment and metaphylaxis of enzootic pneumonia caused by Mycoplasma hyopneumoniae the marketing authorisation holder provided in vitro susceptibility data, including a recent proprietary study, and clinical data, including field studies.
V podporo indikaciji zdravljenja in metafilakse enzootske pljučnice, ki jo povzroča Mycoplasma hyopneumoniae, je imetnik dovoljenja za promet predložil podatke o občutljivosti in vitro, vključno z nedavno lastno študijo, in klinične podatke, vključno s študijami na terenu.
To support the proposed harmonised indication for treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens, the marketing authorisation holder presented in vitro susceptibility data, including a recent proprietary study from 2016, clinical studies and data from the scientific literature.
V podporo predlagani usklajeni indikaciji za zdravljenje in metafilakso nekrotičnega enteritisa, ki ga povzroča Clostridium perfringens, je imetnik dovoljenja za promet predložil podatke o občutljivosti in vitro, vključno z nedavno lastno študijo iz leta 2016, klinične študije in podatke iz strokovne literature.
• Withdrawal periods.
• odmerjanje,
In support of the indication for treatment and metaphylaxis of enzootic pneumonia caused by Mycoplasma hyopneumoniae the marketing authorisation holder provided in vitro susceptibility data including a recent proprietary study and clinical data including field studies.
V podporo indikaciji za zdravljenje in metafilakso enzootske pljučnice, ki jo povzroča Mycoplasma hyopneumoniae, je imetnik dovoljenja za promet predložil podatke o občutljivosti in vitro, vključno z nedavno lastno študijo in kliničnimi podatki, vključno s študijami na terenu.
SPECIAL WARNING(S)
POSEBNO(A) OPOZORILO(A), ČE JE/SO POTREBNO(A)
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
NAVODILO ZA UPORABO Lincocin 400 mg/g prašek za dajanje v vodo za pitje IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
On rare occasions some pigs may show reddening of the skin and mild irritable behaviour.
Med zdravljenjem so posamezne živali lahko nemirne, slabo jejo, nekatere dobijo rahlo pordelo kožo.
However, there was no definitive evidence that strains of C. perfringens with high MICs for lincomycin may be clinically resistant.
Ugotovljeno je bilo, da se vzorec občutljivosti C. perfringens za linkomicin v zadnjih 25 letih ni bistveno spremenil, vendar ni bilo dokončnega dokaza, da so sevi C. perfringens z visoko vrednostjo MIK linkomicina lahko klinično odporni.